FREDERICK, Md., July 23 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today that Ream Surgical Ltd. has signed an agreement and issued their initial purchase order for the distribution of ActiPatch in the United Kingdom. The initial order shipped on July 20th.
Ream Surgical joins the growing list of international distributors for ActiPatch Therapy. BioElectronics has signed agreements in place and shipping has commenced to Germany, Kuwait, Singapore, Turkey, Panama, Canada and Mexico.
“We are pleased to have aligned BioElectronics Corporation with Ream Surgical Ltd. to bring the benefits of ActiPatch healing to the United Kingdom. We have found Ream’s staff and management to be both experienced and knowledgeable about the medical device market in the U.K. and look forward to a mutually beneficial relationship for years to come,” said Andrew Whelan of BioElectronics.
“Ream Surgical is pleased to be working with BioElectronics to bring the ActiPatch range of products to the U.K. We feel this product will benefit the British public in the overall recovery process and get patients back to normal activities. We look forward to building a close working relationship between the two companies,” said Wayne Jarvis of Ream Surgical.
About Ream Surgical Ltd:
Ream Surgical Ltd. was established in 1995 and is based in Dartford, Kent -- where it has its principle administrative office, extensive workshop facilities and stores. It specializes in the supply and repair of surgical instruments and medical equipment, offering a complete resource for its clients in both NHS Trust and Private Hospital Groups, together with Health Centres, G.P. Surgeries and Group Practices.
For more information visit http://www.reamsurgical.com
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation,+1-301-874-4890, Fax: +1-301-874-6935, info@bioelectronicscorp.com
